Clinical Efficacy Analysis of Pyrazinamide Combined with Levofloxacin in the Treatment of Multi-drug Resistant Tuberculosis
Objective:To explore the effect of pyrazinamide combined with levofloxacin in the treatment of multi-drug resistant tuberculosis(MDR-TB).Methods:A total of 104 patients with MDR-TB treated in a hospital from June 2019 to December 2022 were selected and assigned to the control group and observation group by random number table,with 52 patients in each group.Patients in the control group received levofloxacin in addition to conventional anti-tuberculosis treatment,while those in the observation group received pyrazinamide on top of the treatment given in the control group.The total response rate,sputum negative conversion rate,cavity closure rate,oxidative stress index,inflammatory factors and adverse reactions were compared between the two groups.Results:After treatment,the total response rate in the observation group was higher than that of the control group(P<0.05);the sputum negative conversion rate and cavity closure rate in the observation group were higher than those in the control group(P<0.05);the total antioxidant status(TAS)level in the observation group was higher than that in the control group,while the total oxidant status(TOS)level was lower than that in the control group(P<0.05);the levels of monocyte chemoattractant protein-1(MCP-1),procalcitonin(PCT)and C-reactive protein(CRP)in the observation group were lower than those in the control group(P<0.05).No statistically significant difference in the total incidence of adverse reactions including inappetence and hepatic function abnormal was observed between the two groups(P>0.05).Conclusion:Pyrazinamide combined with levofloxacin in the treatment of MDR-TB can effectively improve the pulmonary inflammatory injury and increase the clearance rate of Mycobacterium tuberculosis,with obvious clinical efficacy and without additional risks of adverse reactions.
万方数据
维普
